MedTrace Logo

Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B

NCT00710216 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-04-20

No results posted yet for this study

Summary

This study examines the effect of telbivudine compared to lamivudine on the early viral kinetics in patients with chronic hepatitis B. The virus Kinetics is measured by the viral load (HBV-DNA) reduction in the serum during the first 12 weeks of therapy.

Conditions

  • Hepatitis B, Chronic

Interventions

DRUG

Lamivudine

100 mg/day

DRUG

Telbivudine

600 mg/day

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • University of Ulm

    lead OTHER

Principal Investigators

  • Nektarios Dikopoulos, MD · University Hospital Ulm

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00710216 on ClinicalTrials.gov